Lisata Therapeutics (LSTA) to Release Quarterly Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Lisata Therapeutics Stock Performance

LSTA opened at $4.55 on Thursday. The stock has a market cap of $40.13 million, a price-to-earnings ratio of -2.14 and a beta of 1.25. The firm’s fifty day moving average is $3.06 and its 200 day moving average is $2.60. Lisata Therapeutics has a fifty-two week low of $1.81 and a fifty-two week high of $4.89.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Zacks Research downgraded Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Thursday, January 22nd. Finally, Brookline Capital Acquisition downgraded Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $23.50.

Hedge Funds Weigh In On Lisata Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Lisata Therapeutics by 6.1% in the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics during the 3rd quarter valued at approximately $37,000. Finally, Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics in the second quarter valued at $32,000. Hedge funds and other institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.